A. Drilon

Publications374
h-index57
Citations13,557
Highly Influential Citations297
Claim Author Page
Author pages are created from data sourced from our academic publisher partnerships and public sources.

Recommended Authors

  • M. Ladanyi
  • 898 Publications • 135,825 Citations
  • G. Riely
  • 492 Publications • 55,257 Citations
  • A. Shaw
  • 464 Publications • 44,740 Citations
  • M. Kris
  • 836 Publications • 75,711 Citations
  • Publications
  • Influence
Efficacy of Larotrectinib in TRK Fusion–Positive Cancers in Adults and Children
TLDR
Larotrectinib had marked and durable antitumor activity in patients with TRK fusion–positive cancer, regardless of the age of the patient or of the tumor type.
Safety and Antitumor Activity of the Multitargeted Pan-TRK, ROS1, and ALK Inhibitor Entrectinib: Combined Results from Two Phase I Trials (ALKA-372-001 and STARTRK-1).
TLDR
Entrectinib was shown to be well tolerated and active against those gene fusions in solid tumors, including in patients with primary or secondary CNS disease, and a complete CNS response was achieved in a patient with SQSTM1-NTRK1-rearranged lung cancer.
Next-Generation Sequencing of Pulmonary Large Cell Neuroendocrine Carcinoma Reveals Small Cell Carcinoma–like and Non–Small Cell Carcinoma–like Subsets
TLDR
While exhibiting predominant similarity with lung adenocarcinoma, NSCLC-like LCNEC harbored several distinctive genomic alterations, including more frequent mutations in NOTCH family genes, implicated as key regulators of neuroendocrine differentiation.
Response to MET inhibitors in patients with stage IV lung adenocarcinomas harboring MET mutations causing exon 14 skipping.
TLDR
Responses to the MET inhibitors crizotinib and cabozantinib in patients with lung adenocarcinomas harboring MET exon 14 splice site mutations are reported, identifying a new potential therapeutic target in this disease.
Response to Cabozantinib in patients with RET fusion-positive lung adenocarcinomas.
TLDR
Preliminary data for the first three patients treated with the RET inhibitor cabozantinib on a prospective phase II trial for patients with RET fusion-positive NSCLCs show confirmed partial responses were observed in 2 patients, including one harboring a novel TRIM33-RET fusion.
Targeting MET in Lung Cancer: Will Expectations Finally Be MET?
TLDR
The biology and clinical significance behind MET proto‐oncogene receptor tyrosine kinase (MET) exon 14 alterations andMET amplification in NSCLC are explored, the role of MET amplification in the setting of acquired resistance to EGFR tyrosINE kinase inhibitor therapy in EGFR‐mutant NSCLCs is explored, and the history of MET pathway inhibitor drug development inNSCLC is highlighted.
Cabozantinib in patients with advanced RET-rearranged non-small-cell lung cancer: an open-label, single-centre, phase 2, single-arm trial.
TLDR
The study met its primary endpoint, with confirmed partial responses seen in seven of 25 response-assessable patients, and defined RET rearrangements as actionable drivers in patients with lung cancers.
Targeting RET in Patients With RET-Rearranged Lung Cancers: Results From the Global, Multicenter RET Registry.
TLDR
The results of an international registry of patients with RET-rearranged NSCLCs, providing the largest data set, to the authors' knowledge, on outcomes of RET-directed therapy thus far, are presented.
Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1-2 trials.
TLDR
Results show that entrectinib induced durable and clinically meaningful responses in patients with NTRK fusion-positive solid tumours, and was well tolerated with a manageable safety profile.
Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry
TLDR
In certain subgroups, PFS was positively associated with PD-L1 expression (KRAS, EGFR) and with smoking status (BRAF, HER2) and the lack of response in the ALK group was notable.
...
1
2
3
4
5
...